ReviewFrontiers in pharmacology2020
Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.BMC infectious diseases · 2023Trial
- Prescription patterns in an intensive care unit of COVID-19 patients in Bangladesh: A cross-sectional study.Health science reports · 2023Article
- Thrombosis and Anticoagulation Strategies in Patients with COVID-19 Including Japanese Perspective.Journal of atherosclerosis and thrombosis · 2023Article
- The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries.Frontiers in pharmacology · 2023Article
- Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.Inflammopharmacology · 2022Review
- Circulating and Salivary NGF and BDNF Levels in SARS-CoV-2 Infection: Potential Predictor Biomarkers of COVID-19 Disease-Preliminary Data.Journal of personalized medicine · 2022Article
- Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy.Journal of clinical medicine · 2022Article
- Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials.Journal of clinical medicine · 2022Review
- Anti-Inflammatory Effects and Decreased Formation of Neutrophil Extracellular Traps by Enoxaparin in COVID-19 Patients.International journal of molecular sciences · 2022Article
- Review
- Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.Drug development research · 2022Review
- [Enoxaparin dose associated with decreased risk of death in COVID-19].Revista medica del Instituto Mexicano del Seguro Social · 2022Observational
- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?Cancers · 2021Review
- High versus Standard Intensity of Thromboprophylaxis in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2021Review
- COVID-19 with underdiagnosed influenza B and parainfluenza-2 co-infections in Saudi Arabia: Two case reports.Journal of infection and public health · 2021Article
- Elucidating the Binding Mode between Heparin and Inflammatory Cytokines by Molecular Modeling.ChemistryOpen · 2021Article
- The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper.Thrombosis and haemostasis · 2021Article
- Towards better understanding of the heparin role in NETosis: feasibility of using native mass spectrometry to monitor interactions of neutrophil elastase with heparin oligomers.International journal of mass spectrometry · 2021Article
- Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients.Drugs & aging · 2021Article
- Authors' response to the Letter to the Editor regarding: Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations.Multidisciplinary respiratory medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impact of the COVID-19 pandemic has been dramatic worldwide, with China, Italy, and now US at its epicenter. Researchers and clinicians are studying and testing different approaches in the attempt to prevent the infection and minimize its severity. Major efforts are focused on optimizing mechanical ventilation, antiviral, and supportive treatment; however, the role of heparin and low molecular weight (LMW) heparin in this setting has been largely overlooked. This review summarizes the available evidence about the role of heparan sulfate as a key entry mechanism for SARS-CoV-2; the efficacy of heparin and LMW heparin in counteracting its entry into the cell, the recent experimental findings obtained in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.